For-Robin, a start-up company that grew out of research conducted at the University at Buffalo, has received a $2 million grant from the National Cancer Institute to further study a promising possible cancer treatment.
Kate Rittenhouse-Olson, a professor of biotechnical and clinical laboratory sciences at UB and the company’s president, founded For-Robin in 2012, naming the company after a sister who died from breast cancer.
For-Robin’s main technology is a patented antibody, named JAA-F11, that attaches itself to cancer cells to block the spread of the disease to other parts of the body. The treatment has shown promise in mice and the new NCI grant will support further testing of variations of the antibody in animals.
For-Robin has previously received financial support from NCI and from UB. The company has two full-time researchers, and plans to hire two more in the coming months. It also has several part-time employees.